There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Boston Scientific (BSX – Research Report) and Taysha Gene Therapies (TSHA – Research Report) with bullish sentiments.
Boston Scientific (BSX)
BTIG analyst Marie Thibault maintained a Buy rating on Boston Scientific today and set a price target of $51.00. The company’s shares closed last Tuesday at $45.58.
According to TipRanks.com, Thibault is a 5-star analyst with an average return of 58.9% and a 58.4% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Irhythm Technologies, and Delcath Systems.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Boston Scientific with a $49.61 average price target, representing an 11.2% upside. In a report issued on July 14, Goldman Sachs also maintained a Buy rating on the stock with a $50.00 price target.
Taysha Gene Therapies (TSHA)
Needham analyst Gil Blum reiterated a Buy rating on Taysha Gene Therapies today and set a price target of $45.00. The company’s shares closed last Tuesday at $17.81, close to its 52-week low of $17.66.
According to TipRanks.com, Blum is ranked 0 out of 5 stars with an average return of -21.7% and a 0.0% success rate. Blum covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals, Generation Bio, and Avrobio.
Taysha Gene Therapies has an analyst consensus of Strong Buy, with a price target consensus of $44.25, implying a 143.7% upside from current levels. In a report issued on July 16, William Blair also maintained a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.